Comment from Jonathan Cardenas, transatlantic technology law forum fellow, Stanford Law School
Month: June 2020
Disruptive opportunities with genuine relevance to insurance
GCV spoke with Michaël Niddam, co-founder and managing director of Kamet Ventures about the intersection of health care and insurance tech.
Sector specialist: Rob Coppedge
Rob Coppedge, CEO, Echo Health Ventures
Sector specialist: Richard Osborn
Richard Osborn, managing partner, Telus Ventures
Health sector stays strong
Sector analysis: Health & life sciences
Covid-19 likely to prompt strategy change
Global Corporate Venturing ran a short survey of corporate venture capital investors on the impact of the Covid-19 pandemic in April.
GCV musters CVCs at its first digital forum
Global Corporate Venturing hosted its first virtual conference, GCV Digital Forum, on June 3 and 4 with a special networking space and ideas challenge.
Look east for our emerging future
June issue editorial by James Mawson, editor in chief, Global Corporate Venturing
Europe’s need for a sustainable and equitable investment plan
Europe can respond to the Covid-19 crisis in two ways: restore the past or bounce forward.
CVC easy as 123
When asked for the Global Corporate Venturing agriculture technology supplement in March, why there is such a boom, Daria Batukhtina, business development manager at Kubota Group, a Japan-based agriculture machinery maker, said: “Business is not as usual.”
CureVac gets a $339m kick from KfW
The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.
Epic Games approaches $750m round
Endeavor Group is likely to sell shares in the game developer, which is near to raising money in a round that will boost its valuation from $15bn to $17bn.
Burning Rock blazes a trail on to public markets
The Legend Holdings and Eli Lilly-backed cancer diagnostics technology developer floated above its range to raise $223m and its shares have since risen 40%.
Vaxcyte racks up $250m in IPO
Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.